Cefuroxime Axetil
The oral prodrug formulation of cefuroxime is hydrolyzed in the intestinal mucosa to release active cefuroxime. It is used for the outpatient treatment of mild to moderate infections including sinusitis, bronchitis, and urinary tract infections. It should be taken with food to maximize bioavailability.
Peso molecular
510,5000 g/mol
LogP
0,90
TPSA
214,00 Ų
Regla de cinco de Lipinski
No cumple
Áreas terapéuticas
Mecanismo de acción
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OC(C)OC(C)=O)=C(COC(N)=O)CS[C@H]12)c1ccco1
InChI
InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1
Molecular Formula
C20H22N4O10S
HBD / HBA
2 / 12
Enlaces Rotables
12
Átomos Pesados
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The oral prodrug formulation of cefuroxime is hydrolyzed in the intestinal mucosa to release active cefuroxime. It is used for the outpatient treatment of mild to moderate infections including sinusitis, bronchitis, and urinary tract infections. It should be taken with food to maximize bioavailability.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Cefuroxime Axetil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1095930. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6321416. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefuroxime-axetil"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefuroxime-axetil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefuroxime-axetil/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefuroxime-axetil/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefuroxime-axetil"></drugfyi-drug>